CGON (CG Oncology, Inc.) Pangali Forward P/E

Simbol resmi perusahaan CG Oncology (CGON)

The future of CG Oncology, Inc. (CGON) is based on an extreme dependence on a single platform targeting bladder cancer. The company's success relies on the commercialization of cretostimogene and FDA approval. The company's forward P/E ratio visualizes these expectations, and the value is currently held at 0.00. Business growth is supported by strategic engagement with scientific communities to create innovative immunotherapy.

CG Oncology - Pangali Forward P/E CGON (periode 21.02.2024 - 17.11.2026)

Ringkesan rincian data analitis CG Oncology, Inc. (CGON)

- rega saiki lan proyeksi nilai saham:
Analisis fundamental perusahaan:CG Oncology Inc
Produk merek CG Oncology Therapeutics

CG Oncology, Inc. (CGON) is currently in a phase of intensive investment in clinical trials, meaning the company's forward P/E reflects market expectations regarding the transition from capital burn to profitability. This indicator measures the cost per unit of projected earnings, demonstrating how the potential monopoly status of its bladder cancer therapy and low production costs create powerful operating leverage for capitalization.

Analisis pesaing

Pangali Forward P/E ONC|HALO (Halozyme Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (revmed.com)|AAPG - Prakiraan rega marang bathi|URGN: Prakiraan rega marang bathi|BCAX - Pangali Forward P/E|Personalis Corp (PSNL) - Rega marang bathi mangsa ngarep|Erasca Corp - Pangali mangsa ngarep rega marang bathi|DCTH (Delcath Systems Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Y-mAbs Therapeutics, Inc. YMAB|Pangali Forward P/E AURA|Prakiraan rega marang bathi Candel Therapeutics, Inc. CADL|Pangali Forward P/E ARAY (Accuray, Inc.)|SELLAS Life Sciences - Rega marang bathi mangsa ngarep|ACTU: Prakiraan rega marang bathi|Citius Oncology, Inc. - Rasio kapitalisasi marang bathi mangsa ngarep|HURA (TuHURA Biosciences) - Prakiraan rega marang bathi|TARA: Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi FATE|WHWK: Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi TCRX (TScan Therapeutics Inc)|Kapitalisasi marang proyeksi bathi Champions Oncology Inc|Pangali Forward P/E XBIT (XBiotech Inc.)|Pangali mangsa ngarep rega marang bathi CVM|OS Therapies Inc. - Pangali Forward P/E|RADX - Pangali Forward P/E|ARTV: Pangali Forward P/E|ANL: Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi VERU|TPST: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep xiliotx.com (XLO)|Renovaro - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Mural Oncology MURA|KAPA - Prakiraan rega marang bathi|OKUR - Rega marang bathi mangsa ngarep|GDTC - Pangali Forward P/E|Curis, Inc. (CRIS) - Rega marang bathi mangsa ngarep|Prakiraan rega marang bathi Apollomics, Inc.|Prakiraan rega marang bathi THAR|Rasio rega marang bathi mangsa ngarep ADVB (Advanced Biomed)|Prakiraan rega marang bathi GNPX (Genprex, Inc)|CLDI: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep sunshinebiopharma.com SBFM|XBIO - Prakiraan rega marang bathi|SLRX: Prakiraan rega marang bathi|Purple Biotech - Rasio kapitalisasi marang bathi mangsa ngarep|American Oncology Network (AONC) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep BGNE|Prakiraan rega marang bathi CKPT|Rega marang bathi mangsa ngarep ELEV|Pangali Forward P/E ICAD|Pangali Forward P/E Ikena Oncology Inc. (IKNA)|Pangali Forward P/E NTBL (Notable Labs Ltd)|Kapitalisasi marang proyeksi bathi Viracta Therapeutics (VIRX)|MOR: Prakiraan rega marang bathi|NAYA (NAYA Bio) - Rasio rega marang bathi mangsa ngarep|AAPGV: Pangali Forward P/E